SCHEMBL4261073

SCHEMBL4261073

N[C@@H](CO)C(=O)OC(=O)[C@@H](N)Cc1c[nH]c2ccccc12

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.67
KDM4E B2RXH2 2/20 0.67
MEN1 O00255 2/20 0.67
LMNA P02545 2/20 0.67
KMT2A Q03164 2/20 0.67
MPO P05164 1/20 0.67
TSHR P16473 1/20 0.67
BLM P54132 1/20 0.67
PMP22 Q01453 1/20 0.67
HIF1A Q16665 1/20 0.67
TACR1 P25103 2/20 0.61
HTR2A P28223 2/20 0.54
ADRB1 P08588 1/20 0.54
HTR1A P08908 1/20 0.54
ADRA2A P08913 1/20 0.54
SLC6A2 P23975 1/20 0.54
HTR1D P28221 1/20 0.54
HTR1B P28222 1/20 0.54
HTR2C P28335 1/20 0.54
HTR1E P28566 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL475351 0.95 MAPT (0.74) MAPTKDM4EMEN1LMNAKMT2A
SCHEMBL289044 0.95 MAPT (0.74) MAPTKDM4EMEN1LMNAKMT2A
SCHEMBL27645874 0.90 MAPT (0.67) MAPTKDM4EMEN1LMNAKMT2A
SCHEMBL21059260 0.89 MAPT (0.70) MAPTKDM4EMEN1LMNAKMT2A
SCHEMBL120931 0.88 KDM4E (0.69) MAPTKDM4EMEN1LMNAKMT2A
SCHEMBL8406415 0.88 MAPT (0.65) MAPTKDM4EMEN1LMNAKMT2A
SCHEMBL5065255 0.88 KDM4E (0.65) MAPTKDM4EMEN1LMNAKMT2A
SCHEMBL17503190 0.88 MAPT (0.72) MAPTKDM4EMEN1LMNAKMT2A
SCHEMBL1640627 0.88 MAPT (0.68) MAPTKDM4EMEN1LMNAKMT2A
SCHEMBL626831 0.88 MAPT (0.72) MAPTKDM4EMEN1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4149493-A1 METHOD OF TREATMENT OF CANCER OR TUMOUR Adaptimmune Limited (GB) 2023-03-22 EP disclosed
EP-4149492-A1 MODIFIED IPSCS Adaptimmune Limited (GB) 2023-03-22 EP disclosed
EP-4149631-A1 METHOD OF TREATMENT OF CANCER OR TUMOUR Adaptimmune Limited (GB) 2023-03-22 EP disclosed
WO-2021229234-A1 METHOD OF TREATMENT OF CANCER OR TUMOUR ADAPTIMMUNE LIMITED (GB) 2021-11-18 WO disclosed
WO-2021229235-A1 METHOD OF TREATMENT OF CANCER OR TUMOUR ADAPTIMMUNE LIMITED (GB) 2021-11-18 WO disclosed
WO-2021229212-A1 MODIFIED IPSCS ADAPTIMMUNE LIMITED (GB) 2021-11-18 WO disclosed
CN-106148311-B A kind of mutant of D-Psicose -3- epimerase and its application 上海立足生物科技有限公司 2019-06-21 CN disclosed
CN-107746426-A Wild almond protein sources α Glucosidase inhibitor peptides through protease P rote AX enzymolysis and preparation method thereof 重庆三峡学院 2018-03-02 CN disclosed
CN-107698659-A Wild almond protein sources ɑ Glucosidase inhibitor peptides through protease M enzymolysis and preparation method thereof 重庆三峡学院 2018-02-16 CN disclosed
CN-105622727-A Method for synthesizing leuprorelin by solid phase and liquid phase WUXI ASIAPEPTIDE BIOTECHNOLOGY CO LTD 2016-06-01 CN disclosed
US-20140187482-A1 INSULIN PREPARATION THE DOSHISHA (JP) 2014-07-03 US disclosed
US-20090023188-A1 Heparin/heparosan synthase from P. multocida and methods of making and using same NATIONAL SCIENCE FOUNDATION 2009-01-22 US disclosed
EP-0498665-B1 Hydroxamic acids derivatives, process for their preparation and use thereof BRITISH BIOTECH PHARM (GB) 1996-04-24 EP disclosed